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Mutations in POGLUT1, Encoding
Protein O-Glucosyltransferase 1, Cause
Autosomal-Dominant Dowling-Degos Disease
F. Buket Basmanav,1,16 Ana-Maria Oprisoreanu,2,16 Sandra M. Pasternack,1,16 Holger Thiele,3
Gu¨nter Fritz,4 Jo¨rg Wenzel,5 Leopold Gro¨ßer,6 Maria Wehner,1 Sabrina Wolf,1 Christina Fagerberg,7
Anette Bygum,8 Janine Altmu¨ller,3 Arno Ru¨tten,9 Laurent Parmentier,10 Laila El Shabrawi-Caelen,11
Christian Hafner,6 Peter Nu¨rnberg,3,12,13 Roland Kruse,14 Susanne Schoch,2 Sandra Hanneken,15
and Regina C. Betz1,*
Dowling-Degos disease (DDD) is an autosomal-dominant genodermatosis characterized by progressive and disfiguring reticulate hyper-
pigmentation. We previously identified loss-of-function mutations in KRT5 but were only able to detect pathogenic mutations in fewer
than half of our subjects. To identify additional causes of DDD, we performed exome sequencing in five unrelated affected individuals
without mutations in KRT5. Data analysis identified three heterozygous mutations from these individuals, all within the same gene.
These mutations, namely c.11G>A (p.Trp4*), c.652C>T (p.Arg218*), and c.798-2A>C, are within POGLUT1, which encodes protein
O-glucosyltransferase 1. Further screening of unexplained cases for POGLUT1 identified six additional mutations, as well as two of
the above describedmutations. Immunohistochemistry of skin biopsies of affected individuals with POGLUT1mutations showed signif-
icantly weaker POGLUT1 staining in comparison to healthy controls with strong localization of POGLUT1 in the upper parts of the
epidermis. Immunoblot analysis revealed that translation of either wild-type (WT) POGLUT1 or of the protein carrying the p.Arg279Trp
substitution led to the expected size of about 50 kDa, whereas the c.652C>T (p.Arg218*) mutation led to translation of a truncated pro-
tein of about 30 kDa. Immunofluorescence analysis identified a colocalization of the WT protein with the endoplasmic reticulum and a
notable aggregating pattern for the truncated protein. Recently, mutations in POFUT1, which encodes protein O-fucosyltransferase 1,
were also reported to be responsible for DDD. Interestingly, both POGLUT1 and POFUT1 are essential regulators of Notch activity.
Our results furthermore emphasize the important role of the Notch pathway in pigmentation and keratinocyte morphology.Dowling-Degos disease (DDD [MIM 179850, MIM
615327]) is an autosomal-dominant form of a reticulate
pigmentary disorder. This rare genodermatosis was first
described by Dowling and Freudenthal in 19381 and was
termed ‘‘dermatose reticule´e des plis’’ by Degos and
Ossipowski (1954).2 Affected individuals develop a postpu-
bertal reticulate hyperpigmentation that is progressive and
disfiguring, and small hyperkeratotic dark-brown papules
that affect the flexures, large skin folds, trunk, face, and
extremities. Pruritus and/or burning sensations might
also feature in clinical presentations.3 The phenotype can
be triggered in some individuals by UV light, mechanical
stimulation, or sweating. Histology shows filiform epithe-
lial downgrowth of epidermal rete ridges, with a con-
centration of melanin at the tips.4 No effective therapy is
yet available.
In 2006, we identified loss-of-function mutations in
KRT5 (MIM 148040) encoding keratin 5, in two large
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The Amersimplex cases.4 Additional mutations in KRT5 responsible
for DDD were also reported.5–8 In subsequent years, we
screened more than 40 individuals with DDD and found
KRT5 mutations in fewer than 50%, with only 16 simplex
and familial cases.9,10 Thus, the causes of a large number of
unsolved cases of DDD remain to be explained. In some
individuals with DDD, who had originally been diagnosed
with Galli-Galli disease (GGD), the additional histopatho-
logical feature of acantholysis was observed. The clinical
presentation and the genetic backgrounds of these
individuals indicated that GGD is a variant of DDD and
not a distinct disease entity.6,10,11 Another locus for DDD
was identified in an affected Chinese family; this locus is
on chromosome 17p13.3, but the responsible mutation
has not been identified to date.12 Additionally, recent
studies of two Chinese families with DDD led to the iden-
tification of mutations in POFUT1 (MIM 607491), which
encodes protein O-fucosyltransferase 1 from the Notch
pathway.13epartment of Neuropathology and Department of Epileptology, University
iversity of Cologne, D-50931 Cologne, Germany; 4Department of Neuropa-
Department of Dermatology, University of Bonn, D-53127 Bonn, Germany;
, Germany; 7Department of Clinical Genetics, Odense University Hospital,
dense University Hospital, DK-5000 Odense, Denmark; 9Laboratory of Der-
Dermatology, Berne University Hospital, CH-3008 Berne, Switzerland;
ia; 12Cluster of Excellence on Cellular Stress Responses in Aging-Associated
cular Medicine Cologne, University of Cologne, 50931 Cologne, Germany;
rmatology, University Hospital Du¨sseldorf, D-40225 Du¨sseldorf, Germany
y of Human Genetics. All rights reserved.
ican Journal of Human Genetics 94, 135–143, January 2, 2014 135
Figure 1. Clinical Appearance and Pedigrees
(A–F) Reticulate hyperpigmentation and hyperkeratotic brown papules on the back (A), breast (B), trunk (C), arm (D), and legs (E and F)
of affected individuals.
(G and H) Pedigrees with two affected individuals. Affected family members are shown in black; circles and squares denote females and
males, respectively. Both individuals II:1 (G and H) were used for exome sequencing.Here, we describe the identification of nine different
mutations in POGLUT1 (RefSeq accession number
NM_152305.2) from 13 unrelated individuals with DDD.
POGLUT1 encodes protein O-glucosyltransferase 1 and is
a part of the Notch signaling pathway.14,15 Further studies
including immunohistochemistry, immunofluorescence,
and immunoblotting supported the pathogenicity of the
identified mutations.
We used the whole-exome sequencing technology to
identify other genetic causes of DDD. Five unrelated indi-
viduals with comparable DDD phenotypes were selected
for sequencing under the assumption that any gene
harboring rare variants in all individuals might be a DDD
candidate. The age of onset in the five individuals varied
between 18 and 53 years. These individuals were all
described and characterized previously under a distinct
clinical subtype suggested for DDD/Galli-Galli disease.9
Specifically, affected individuals presented with a dissemi-
nated pattern of brownish macular and lentiginous lesions
on the extremities, trunk/back and neck without the
typical domination of the flexural folds observed in clas-
sical DDD (Figures 1A–1F).9 Among the five selected indi-
viduals with DDD, three reported no family history of
DDD. One male individual reported that his father was136 The American Journal of Human Genetics 94, 135–143, January 2affected by skin abnormalities similar to his own (Fig-
ure 1G), and one female individual reported that her sister
and probably her mother exhibited skin abnormalities
similar to her own (Figure 1H).
Ethical approval was obtained from the ethics com-
mittee of the Medical Faculty of the University of Du¨ssel-
dorf and the participants provided written informed
consent prior to blood sampling. The study was conducted
in concordance with the Declaration of Helsinki Princi-
ples. DNA was extracted from peripheral blood leukocytes
according to standard methods.
For whole-exome sequencing, we fragmented 1 mg of
DNA with sonication technology (Bioruptor, Diagenode,
Lie`ge, Belgium). The fragments were end-repaired and
adaptor-ligated, including incorporation of sample index
barcodes. After size selection, we subjected a pool of all 5
libraries to an enrichment process with the SeqCap EZ
Human Exome Library version 2.0 kit (Roche NimbleGen).
The final libraries were sequenced on an Illumina HiSeq
2000 sequencing instrument (Illumina) with a paired-end
2 3 100 bp protocol. This resulted in 6.27.3 Gb of map-
ped sequences (on average 6.8 Gb), a mean coverage of
68–803 (on average 753) and 303 coverage of 82–86%
(on average 84%) of the target sequences. The Varbank, 2014
AB
Figure 2. Position of Mutations in POGLUT1 and Verification of Mutations Identified by Exome Sequencing
(A) Cartoon depicting the exon structure of POGLUT1. All identifiedmutations aremarked by arrow heads. Themutations are defined on
nucleotide and protein levels. The number of individuals carrying each mutation is denoted with the number of squares. Red squares
indicate mutations identified by exome sequencing.
(B) All three mutations identified by exome sequencing were verified by Sanger sequencing. The mutated sequences are given in
comparison to WT sequences.pipeline v.2.1 and interface were used for data analysis and
filtering (unpublished data, H.T., J.A., and P.N.; see Table S1
available online). The data were filtered for high-quality
rare (MAF < 0.005) autosomal variants and attention was
focused on genes with the highest burden of functional
variants in individuals with DDD.
Sequencing data analysis identified a single gene,
POGLUT1, which harbors heterozygous nonsense or splice
site mutations in all five affected individuals (Figure 2).
One of the investigated individuals showed a guanine-to-
adenine transition at nucleotide position 11 leading to a
stop codon (c.11G>A [p.Trp4*]). We identified another
nonsense mutation in two further individuals at nucleo-
tide position 652 (c.652C>T [p.Arg218*]; among them
individual II:1, Figure 1G). In the remaining two individ-
uals, we identified a mutation at a splice site (c.798-
2A>C; among them individual II:1, Figure 1H). The splice
site mutation was also identified in the sister of individual
II:2 (Figure 1H; data not shown). All three variants
were confirmed by Sanger sequencing using the BigDye
Terminator v1.1 Cycle Sequencing kit (Applied Bio-
systems) and an ABI 3100 genetic analyzer (Applied
Biosystems) (Figure 2B).
In addition, we screened further individuals from our
DDD cohort for mutations in POGLUT1. Primer sequences
for amplification of POGLUT1 exons are listed in the sup-
plemental information (Table S2). We identified c.11G>A
in a single person, c.798-2A>C in a single person, and
additional mutations in six individuals (Table 1;
Figure 2A; Figure S1). One of these mutations, c.394C>T
(p.Arg132*), which leads to a premature stop codon, is
reported in the 1000 Genomes database as the variant
rs140695299 with a frequency of 1 in 1,092 individuals.
Due to the low incidence frequency and the late age of
onset of the disease, it is likely that this mutation and
two further very rare (combined MAF < 0.0002) frameshift
and splice site mutations (c.898 del1 [p.Phe300Serfs*6] andThe Amerc.1023-2A>C, respectively) reported in databases also lead
to the hyperpigmentation disorder, and that DDD might
be more common than reported. None of the other identi-
fied mutations were found in dbSNP137, ESP, or 1000
Genomes databases. Unfortunately, mostly as a result of
the late age of onset of the disease, it was not possible to
get blood samples from any parents of our individuals or
any affected children. In total, we identified nine different
heterozygous mutations in a total of 13 individuals with
DDD, including nonsense, splice site, missense, insertion,
and deletion mutations. We therefore suggest that
POGLUT1 is a gene, mutations in which are responsible
for DDD. Of note, one of the nonsense mutations is
located at the very beginning of the protein (p.Trp4*).
Therefore, it is very likely that the mRNA transcript with
this mutation is affected by nonsense-mediated mRNA
decaymaking haploinsufficiency themost plausible mech-
anism for autosomal-dominant inheritance.
Of interest, the observation of prominent involvement
of nonflexural areas in individuals with POGLUT1 muta-
tions in comparison to the individuals with KRT5 muta-
tions who present with typical domination of the flexural
folds9 is suggestive of a correlation between the gene in
which mutations are harbored and the DDD phenotype
displayed by the affected individuals.
POGLUT1 is located on chromosome 3q13.33 and has a
1.179 bp open reading frame consisting of 11 coding
exons.16 POGLUT1 encodes the 392 amino acid pro-
tein POGLUT1, alternatively termed KTELC1, C3orf9,
hCLP46, and Rumi, among others. POGLUT1 constitutes
protein O-glucosyltransferase 1, which adds O-linked
glucose to the epidermal growth factor-like (EGF) repeats
of Notch receptors.15,17,18
The mutations identified in our individuals with DDD
are predicted to have a major impact on the transla-
tion or the structure of POGLUT1. POGLUT1 is ortho-
logous to several other structurally well-characterizedican Journal of Human Genetics 94, 135–143, January 2, 2014 137
Table 1. POGLUT1 Mutations Identified in 13 Individuals with DDD
Mutation Protein Alteration Number of Individuals Origin of the Individuals References
c.11G>A p.Trp4* 2 Germany, Denmark Hanneken et al., 2011
This study
c.205C>T p.Arg69* 1 Switzerland This study
c.394C>T p.Arg132* 1 Germany This study
c.635C>G p.Ser212* 1 Germany This study
c.652C>T p.Arg218* 2 Germany Hanneken et al., 2011
c.798-2A>C - 3 Germany Hanneken et al., 2011
c.833_834insC Arg279Profs*3 1 Germany Mauerer et al., 201042
c.835C>T p.Arg279Trp 1 Germany This study
c.1023_1025delG p.Gly342Glufs*22 1 Germany This studyglucosyltransferases from viruses or bacteria. The effects of
the different POGLUT1mutations on the resultant protein
were predicted on the basis of a homology model (Figures
3A, 3B, and 3E; Figure S2). Amodel of POGLUT1was gener-
ated with Modeler.19–22 Alignments of POGLUT1 with
sequences of template structures were generated with the
HHPred server.23 The model was manually adjusted with
Coot24 and figures were generated with PyMol.25 As in or-
thologous glucosyltransferases, POGLUT1 is composed of
an N-terminal (residues 1–180) and a C-terminal (residues
181–392) domain that together form a large binding
pocket for the substrate UDP-glucose at the domain inter-
face (Figure 3A). The arrangement of the two domains
is stabilized by a long C-terminal helix, whereby the
C-terminal end of the helix is anchored in the N-terminal
domain. The mutations causing a translation stop lead to
truncated variants of POGLUT1 that lack major parts or
essential residues resulting in the loss of the substrate bind-
ing site (Figure S2). The truncated form p.Arg132* is
missing parts of the N-terminal domain as well as the
entire C-terminal domain. The mutants p.Ser212* and
p.Arg218*, as well as p.Arg279Profs*3, lack parts of the sub-
strate-binding site essential for high-affinity binding of
UDP-glucose. p.Gly342Glufs*22 is missing in part the
long C-terminal helix causing most likely a disassembly
of the N- and C-terminal domains (Figure S2). We analyzed
the effects of the splice site mutation c.798-2A>C by total
RNA isolation from the mutation carrier individual
followed by reverse transcription of total mRNA into
cDNA and POGLUT1 sequencing. We showed that this
mutation leads to abolishment of exon 9, which would
result in loss of residues 267–322 in the translated protein
(Figure S3). This large deletion will abolish correct folding
of the C-terminal domain of POGLUT1. Moreover, a num-
ber of residues forming the substrate binding site will be
missing, and therefore we anticipate that this mutant is
also inactive. The p.Arg279Trp substitution (Figure 3C)
leads to the replacement of a highly conserved arginine
(Figure 3D) with the dissimilar amino acid tryptophan.
The homology model revealed that Arg279 is particularly138 The American Journal of Human Genetics 94, 135–143, January 2involved in binding the UDP-glucose substrate. In the
orthologous glucosyltransferase of T4 phage, the
guanidinium group of the corresponding arginine residue
forms two salt bridges with the diphosphate moiety of
UDP-glucose and is required to bind the substrate with
high affinity.26,27 In the homology model, Arg279 can
adopt a similar conformation to bind UDP-glucose (Figure
3B). Substitution by tryptophan disrupts the interaction
with the substrate and, moreover, the bulky side chain of
tryptophan might hinder access of the substrate to the
binding site (Figure 3E).
To analyze the localization pattern of POGLUT1, we
investigated skin biopsies from healthy and affected indi-
viduals by using immunohistochemistry. Sections were
prepared from formalin-fixed, paraffin-embedded skin
biopsies obtained by plastic surgery from four individuals
with DDD and different POGLUT1 mutations (nonsense
and splice site) and from four healthy controls with
normal skin. Standard H&E and periodic acid-Schiff stain-
ing was performed for diagnostic purposes. POGLUT1
localization was analyzed using polyclonal anti-POGLUT1
antibody. Results were evaluated on blinded specimens by
an experienced dermatopathologist (J.W.) as described
previously.28
Histologically, skin lesions from individuals with DDD
showed a digitiform reteacanthosis with pronounced
hyperpigmentation at the tips of the rete ridges, some
small horn cysts, minor acantholysis, and focal hypergra-
nulosis (Figure S4). In immunohistology, we found
POGLUT1 to be prominently present in the epidermis of
healthy controls, especially in the upper parts (stratum
spinosum and stratum granulosum, Figure 4A).
The strong POGLUT1 staining in thematured parts of the
epidermis might be indicative that POGLUT1 is important
for the correct differentiation of the epidermal layer and
might emphasize an important role for POGLUT1 in the
development of the epidermis. On the other hand,
POGLUT1 staining was about 50% weaker in lesional skin
of individuals with DDD in comparison to healthy
controls (mean staining intensity, 1.755 0.25 SEM versus, 2014
AC D E
B Figure 3. Protein Modeling of Wild-Type
and Mutant POGLUT1
(A) POGLUT1 is composed of two major
domains; the N-terminal domain (residues
1–180; green) and the C-terminal domain
(residues 181–349; magenta) together form
a binding pocket for the substrate UDP-
glucose (stick model; yellow) at the domain
interface. A long C-terminal helix (residues
350–384; blue) stabilizes the arrangement
of the two domains.
(B) Arg279 is critically involved in UDP-
glucose binding forming two salt bridges to
oxygen atoms of the diphosphate moiety
of UDP-glucose. UDP-glucose is shown as
stick model with carbon shown in yellow,
nitrogen in blue, phosphor in orange, and
oxygen in red. Arg279 is shown as stick
model with carbon inmagenta and nitrogen
atoms in blue. The salt bridges are indicated
as broken lines.
(C) Sequence analysis showing the mutant
and WT sequences for the missense muta-
tion leading to substitution of an argi-
nine residue with tryptophan (c.835C>T
[p.Arg279Trp]).
(D) Partial amino acid sequence of
human POGLUT1 in comparison with or-
thologs from other species. Arginine residue
depicted with red is highly conserved across
different species.
(E) p.Arg279Trp leads to the substitution of this arginine residue with tryptophan. Loss of the interaction between arginine and the
phosphate group of UDP-glucose will largely decrease the affinity to the substrate.Moreover, the large side chain of Trp279 in themutant
form of the enzymemight block the access of UDP-glucose. The side chain of Trp279 is shown as stick model and Van-der-Waals spheres
in cyan.0.75 5 0.32 SEM, p < 0.05, Mann-Whitney U-test)
(Figure 4A; Figure S5). This observation could be due to
only the WT POGLUT1 being detected by the antibody
and not the truncated forms. This would be in accordance
with the affected individuals having only one copy of the
gene encoding for the WT protein. We next examined
whether the mutated gene variants produce full-length,
truncated, or no POGLUT1. For this purpose, POGLUT1,
WT, and two of the identified mutants (p.Arg218* and
p.Arg279Trp) were fused to N- and C-terminal Strep/FLAG
Tandem Affinity-tags (N-TAP and C-TAP constructs,
respectively) and expressed in HEK293T cells (European
Collection of Cell Cultures [ECACC]) and analyzed by
immunoblotting. Primers used for cloning and mutagen-
esis are listed in the supplemental information (Tables S3
and S4). Immunoblot analysis showed that the WT
construct led to translation of a protein of about 50 kDa
in size, which is in accordance with previous reports.16
While the missense mutation did not alter the molecular
weight, the nonsensemutation resulted in a truncated pro-
tein of about 30 kDa in size (Figure 4B). There were no sig-
nificant differences in the molecular weights between the
N-TAP andC-TAP tagged proteins (Figure S6). The immuno-
blot labeled with anti-POGLUT1 antibody confirmed the
translation of the targeted proteins (Figure 4B; Figure S6).
To determine the subcellular localization of WT and
mutant POGLUT1, we performed immunofluorescenceThe Ameranalysis with transiently transfected HEK293T cells. The
confocal microscopy analyses revealed the colocalization
of the WT POGLUT1 with the endoplasmic reticulum
(ER) for both the N- and C-TAP constructs (Figure 4C;
Figure S7) as previously reported in COS7 cells.16 No signif-
icant differencewas observed in the subcellular localization
of the WT protein and the protein with the p.Arg279Trp
substitution in either of the constructs (Figure 4C;
Figure S7). However, compared to the WT proteins, the
truncated N-TAP-POGLUT1 appeared to form more aggre-
gates, which coincided with an impaired colocalization
with the ER (Figure 4C). This can be explained by the lack
of the C-terminal tetrapeptide sequence KTEL, which is
known to be important for the retention of POGLUT1 in
theER.16 In addition, the stabilizing effect of theC-terminal
helix as shown by homology modeling of POGLUT1
(Figure 3A) might influence the protein conformation and
thus its subcellular localization. In the C-TAP constructs,
however, we did not observe any significant difference in
the localization of the WT and the truncated proteins
(Figure S7). The difference between the two constructs
can be attributed to the position of the tag. In the C-TAP
constructs the amino acid sequence in the vicinity of the
tag is different between the WT and the truncated forms,
whereas it is the same in the N-TAP constructs.
POGLUT1 is part of the Notch signaling pathway, which
is important for cell fate and tissue formation duringican Journal of Human Genetics 94, 135–143, January 2, 2014 139
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Figure 4. Immunohistochemistry on Skin Biopsies, Immunoblotting, and Immunofluorescence Analysis of HEK293T cells Transiently
Expressing Wild-Type and Mutant POGLUT1
(A) For immunohistochemistry, sections were prepared from formalin-fixed, paraffin-embedded skin biopsies obtained by plastic surgery
from individuals with DDD and healthy controls. POGLUT1 localization was analyzed with the polyclonal antibody NBP1-90311
(named KTELC1; Novus Biologicals) at a 1:500 dilution. Visualization was performed with the LSAB2 staining kit (DAKO) with Fast
Red Chromogen.
POGLUT1 was strongly present in the epidermis of healthy controls, especially in the upper parts (the stratum spinosum and stratum
granulosum). POGLUT1 staining was weaker in lesional skin of individuals affected by DDD.
(B) For immunoblotting, WT sequence, sequence bearing mutation c.652C>T (p.Arg218*), and sequence bearing mutation c.835C>T
(p.Arg279Trp) were cloned into the eukaryotic expression vector pAAV-CMV-MCS (Stratagene). HEK293T cells (European Collection
of Cell Cultures [ECACC]) were transiently transfected with the plasmids by the use of Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Forty-eight hr after transfection, cells were lysed in ice cold lysis buffer (50 mM HEPES pH 7.5,
150 mMNaCl, 1% Triton X-100) supplemented with proteinase inhibitors (Roche) for 30 min on ice followed by sonication and centri-
fugation at 14.000 rpm/10 min/4C. Clear supernatant was boiled with SDS-sample buffer at 95C for 5 min and the proteins were
subjected to gel electrophoresis (SDS-PAGE, 10%) followed by transfer to nitrocellulose membrane (Millipore). Immunoblotting was
performedwithmouse anti-Flag (1804; Sigma Aldrich, 1:1.000), rabbit anti-POGLUT1 (NBP1-90311; Novus Biologicals, 1:1.000) primary
antibodies and IRDye secondary antibodies (IRDye 800 goat anti-mouse and IRDye 680 goat anti-rabbit, 1:10.000). Bands of the expected
size were detected for theWT POGLUT1 and the protein with the p.Arg279Trp substitution, whereas the nonsense mutation (c.652C>T
[p.Arg218*]) led to translation of a truncated protein of around 30 kDa.
(C) Immunofluorescence analysis was performedwith transiently transfected HEK293Tcells. Cells were fixed and incubated for 12–14 hr
with mouse anti-Flag (1:400, Sigma-Aldrich) and rabbit anti-PDI (1:200, Abcam) antibodies. After several washing steps, cells were incu-
bated for 40 min with Alexa Fluor 488 goat anti-rabbit, Alexa Fluor 568 goat anti-mouse (1:300, Invitrogen), and DAPI (Invitrogen).
(legend continued on next page)
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embryogenesis and, in adulthood, for differentiation and
stem cell maintenance. Mutations have been found in
various genes of the Notch signaling pathway, including
those encoding receptors and ligands, and have been
shown to cause diverse disorders such as cerebral arteriopa-
thy with subcortical infarcts and leukoencephalopathy
(CADASIL [MIM 125310]),29 spondylocostal dysostosis
(SCDO1 [MIM 277300]),30 Alagille syndrome (ALGS1
[MIM 118450], ALGS2 [MIM 610205]),31,32 Adams-Oliver
syndrome (AOS3 [MIM 614814]), and diverse cardiac disor-
ders and carcinomas.
Besides its role in important developmental processes,
the Notch pathway also plays an important role in skin ho-
meostasis by regulating the proliferation and differentia-
tion dynamics of melanocytes and keratinocytes.33–35
Notch signaling is also suggested to be a key component
in mediating the interactions between melanocytes and
keratinocytes.36–38 This is consistent with our former4 ob-
servations of the irregular shape and size of keratinocytes
in skin biopsies of individuals with DDD. In addition, we
previously reported a haphazard distribution of irregularly
shaped melanosomes as determined by ultrastructural
analysis in individuals affected by DDD with KRT5 muta-
tions.4 Of note, KRT5 is together with KRT14 (MIM
148066) known to be required for normal development
of the basal cells in the epidermis. Loss of KRT5 and
KRT14 expression during epidermal differentiation coin-
cides with increased levels of activated Notch1 in these
cells.39 By immunohistochemistry we also investigated
KRT5 in skin biopsies of POGLUT1 mutation carriers
affected by DDD in comparison to normal skin and skin
from individuals with psoriasis as a positive control. As
expected, KRT5 staining was weak and mostly restricted
to the basal epidermal layer in healthy controls
(Figure S8). On the other hand, KRT5 was prominently pre-
sent within the whole epidermal layer in psoriasis, which is
a disease characterized by disturbed epidermal differentia-
tion. Interestingly, KRT5 was also strongly present within
the lesional DDD skin, not only in the basal epidermal
areas but also in upper parts of the epidermis, which might
suggest a disturbed epidermal differentiation in DDD
(Figure S8). This would also be in accordance with effects
of Notch pathway on keratinocyte differentiation.
Notch deficiencies leading to abnormal pigmentation
have been previously noted. For example, mice depleted
of Notch1 (MIM 190198) andNotch2 (MIM600275) recep-
tors exhibit a progressive and precocious hair graying.36,38
In another example, mice with a conditionally ablated
recombination signal binding protein for immunoglobulin
kappa J region (RBPJ [MIM 147183]), which encodes a tran-Images were acquired at room temperature with a laser-scanning conf
infrared 603water-immersion objective (NA 1.27). For each construc
4.0 acquisition software (Nikon).
The analysis revealed the colocalization of theWT POGLUT1with end
localization patterns of the WT protein and the protein with the a
observed for the truncated protein in comparison to the WT protei
Abbreviations are as follows: HC, healthy control; DDD, Dowling-D
The Amerscriptional regulator of the Notch signaling pathway,
presented with abnormal pigmentation in the dermal
papilla;35,37 this might be considered analogous to the
hyperpigmentation phenotype displayed by our individ-
uals affected by DDD. This abnormal pigmentation in
mice is attributed to a lack of Notch signaling, leading to
aberrant migration of melanoblasts and melanocytes to
ectopic locations.35 These observations, alongside our
data presented here and elsewhere, suggest that deleterious
mutations in POGLUT1 encoding protein O-glucosyltrans-
ferase, lead to a disorder with abnormalities in pigmenta-
tion and keratinocyte morphology.
Fernandez-Valdivia et al. (2011) reported dominant and
recessive Rumi (POGLUT1) mice mutants.15 The Rumi/
recessive knockouts died before embryonic day 9.5 and
showed severe defects in neural tube development, somito-
genesis, cardiogenesis, and vascular remodeling. It was also
shown that Jag1þ/, Rumiþ/ double-heterozygous animals
showed bile duct defects. Heterozygotes with loss of one
copy of Rumi resulted in 50% loss of POGLUT1 activity.15
The heterozygotes did not display any clearly aberrant
skin phenotype,15 but it is possible that mild alterations
to pigmentation would not have been observed.
A recent report by Li et al. (2013) identified mutations in
POFUT1 as being responsible for DDD.13 POGLUT1 and
POFUT1 are both involved in posttranslational modifica-
tion of Notch proteins. POFUT1 adds O-linked fucose to
EGF-like repeats of Notch receptors, whereas POGLUT1
transfers O-linked glucose from UDP-glucose to serine
residues in Notch EGF repeats with the consensus C1-X-
S-X-P-C2.18 Li et al. identified a nonsense mutation and a
single base pair deletion mutation in Chinese individuals
in POFUT1.13 Additional functional studies performed by
the Chinese group, such as morpholino knockdown and
knockdown of POFUT1 in HaCat cells, strongly suggest
that POFUT1 is involved in melanin synthesis.13
Another recent study used whole-exome sequencing to
identify mutations in ADAM10 (MIM 602192) encoding
a disintegrin and metalloproteinase domain 10 as the
cause of another hyperpigmentation disorder, reticulate
acropigmentation of Kitamura (RAK).39 Hyperpigmenta-
tion in RAK is mainly concentrated in the dorsa of the
hand and feet, but it has nevertheless been posited that
DDD and RAK overlap. ADAM10 is another key protein
in the Notch signaling pathway and is required for the
activation of NOTCH1 through a proteolytic mechanism
initiated by ligand-binding.40,41
In summary, the identification of DDD causative muta-
tions in POGLUT1, encoding protein O-glucosyltrans-
ferase 1, contributes to the growing list of genes that, whenocal microscope (Nikon A1/Ti, Nikon) with a CFI Plan Apochromat
t z stack (step: 0.250 um), images were taken with the NIS-Elements
oplasmic reticulum (ER). No significant differencewas observed in
mino acid substitution. However, a more aggregated pattern was
n, which coincided with an impaired colocalization with the ER.
egos disease, IB, immunoblot.
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mutated, are known to be responsible for human hyperpig-
mentation disorders. Our results, in combination with data
describing the effects of mutations in POFUT1, contribute
to a better understanding of the biology of the skin and
emphasize the important role of the Notch pathway in
pigmentation and differentiation of the epidermis.Supplemental Data
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